Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning — A retrospective analysis

Autor: Nilica, Bernhard, Svirydenka, Anna, Fritz, Josef, Bayerschmidt, Steffen, Kroiss, Alexander, Gruber, Leonhard, Virgolini, Irene Johanna

Publikováno v: In Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) May-June 2022 41(3):138-145

Theragnostics in Neuroendocrine Tumors

Autor: Rodrigues, Margarida, Svirydenka, Hanna, Virgolini, Irene

Publikováno v: In PET Clinics July 2021 16(3):365-373

A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

Autor: Thomas Rohban, Henning Grønbæk, Colin G. Miller, Sandy McEwan, Andreas Kjaer, Pierre Terve, Hanna Svirydenka, Irene Virgolini, Shadfar Bahri, Peter Iversen

Publikováno v: EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)
EJNMMI Research
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI Research, vol. 11, no. 1, 84, pp. 1-11 . https://doi.org/10.1186/s13550-021-00819-1
Miller, C G, Grønbæk, H, Virgolini, I, Kjaer, A, Terve, P, Bahri, S, Iversen, P, Svirydenka, H, Rohban, T & McEwan, S 2021, ' A novel read methodology to evaluate the optimal dose of 68 Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours : a phase II clinical trial ', EJNMMI research, vol. 11, no. 84, 84 . https://doi.org/10.1186/s13550-021-00819-1

Background 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the optimal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d254e7679d4aa8dbac9338fa8185578
https://doaj.org/article/4c8b1bb0808c480fadaf97e8afe9d6a7

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT

Autor: Steffen Bayerschmidt, Christian Uprimny, Alexander Stephan Kroiss, Josef Fritz, Bernhard Nilica, Hanna Svirydenka, Clemens Decristoforo, Elisabeth von Guggenberg, Wolfgang Horninger, Irene Johanna Virgolini

Publikováno v: Diagnostics, Vol 11, Iss 7, p 1191 (2021)

Background: 68Ga-PSMA-11 PET/CT is a promising method for the assessment of local recurrence (LR) in prostate cancer (PCa) patients. The aim of this study was to evaluate the diagnostic performance of early 68Ga-PSMA-11 PET imaging in comparison to 6

Externí odkaz: https://doaj.org/article/6f2e62fdead3446ba96e4bab33499071

Nefrotoxicidad y hematotoxicidad un año después de cuatro ciclos de terapia con péptidos marcados con radionúclidos (PRRT) y su impacto en la planificación del tratamiento futuro. Un análisis retrospectivo

Autor: Leonhard Gruber, Steffen Bayerschmidt, Josef Fritz, Irene Virgolini, Bernhard Nilica, Anna Svirydenka, Alexander Kroiss

Publikováno v: Revista Española de Medicina Nuclear e Imagen Molecular. 41:138-145

Resumen Introduccion La nefrotoxicidad y la hematotoxicidad despues de la terapia con peptidos marcados con radionuclidos (PRRT) se han descrito en multiples estudios usando diferentes actividades acumulativas, numero de ciclos o peptidos marcados co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dac2a90eb9dae2452b27960ad4dc9cff
https://doi.org/10.1016/j.remn.2021.03.004